Pre-clinical studies with ALL cell lines and mouse models found that in vitro knock down of CCN2 or treatment with anti-CCN2 antibody could prolong survival (Lu et al. 2014). The gene discussed is CCN2; the disease is acute lymphoblastic leukemia.